文献速递临床试验与 GCP

石榴汁降低炎症性肠病高临床复发风险患者粪钙卫蛋白水平:随机对照试验研究方案

Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-06-06

本随机对照试验纳入病变累及结直肠、稳定治疗至少3个月且临床复发风险高的炎症性肠病患者,随机分为活性补充组(125 mL cv. Wonderful石榴汁)与安慰剂组(125 mL),每日两次、持续12周,主要结局为两组基线与12周间粪中性粒细胞来源蛋白钙卫蛋白的变化。

要点

  • 研究纳入病变累及结直肠、稳定治疗≥3个月且临床复发风险高的炎症性肠病患者。
  • 活性组每日两次每次125 mL cv. Wonderful石榴汁,安慰剂组125 mL,持续12周,双盲随机。
  • 主要结局为两组基线与12周间粪钙卫蛋白变化,次要结局包括转录组与循环炎症标志物等。

核心结论

  • 研究结果将提供石榴汁摄入后粪钙卫蛋白水平可能降低的信息。
  • 研究结果还将展示石榴鞣花单宁的体内代谢,并阐明12周石榴汁摄入对局部和全身炎症标志物的影响。

研究设计与样本

  • 双盲随机对照试验,纳入病变累及结直肠、稳定治疗至少前3个月且临床复发风险高的炎症性肠病患者。
  • 参与者随机分配至活性补充组(125 mL cv. Wonderful石榴汁)或安慰剂组(125 mL),每日两次,持续12周。

主要发现

  • 主要结局为两组基线与12周后粪中性粒细胞来源蛋白钙卫蛋白的变化。
  • 次要结局包括外周血单核细胞和肠道活检的转录组变化、循环炎症标志物及氧化三甲胺水平的变化。
  • 在血浆和尿液样本中鉴定并定量石榴鞣花单宁来源代谢物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory bowel disease (IBD) is a chronic condition characterized by recurrent episodes of intestinal inflammation and is thought to be related to an autoimmune reaction to genetic and environmental factors. Although evidence indicates that a polyphenolic-rich diet plays an important role in modulating aspects of chronic inflammation, few studies have focused on the effect of ellagitannin (ET)-rich food consumption on long-term remission maintenance in IBD patients with a high risk of clinical relapse. Therefore, we hypothesize that supplementation with a pomegranate juice, a naturally rich source of ETs, could significantly modulate the markers of mucosal and systemic inflammation relative to a control group receiving a placebo. METHODS/DESIGN: This double-blind, randomized controlled trial includes patients with IBD involving the colorectum who have been in stable therapy for at least the three previous months and have a high risk of clinical relapse. Participants are randomly allocated to one of two groups: active supplementation (125 mL of cv. Wonderful pomegranate juice) or placebo (125 mL) taken twice daily for 12 weeks. The primary outcome is changes in the fecal neutrophil-derived protein calprotectin, a surrogate marker of mucosal improvement, between the two groups from baseline to 12 weeks later. The secondary outcomes include transcriptomic changes in peripheral blood mononuclear cells and intestinal biopsies and changes in circulating inflammatory markers and trimethylamine-N-oxide levels. Pomegranate ET-derived metabolites are identified and quantified in plasma and urine samples. DISCUSSION: The results will provide information on the possible reduction of fecal calprotectin levels following the consumption of pomegranate juice. The findings will also show the in vivo metabolism of pomegranate ETs. Finally, the effect of 12-week pomegranate juice consumption on local and systemic inflammatory markers will be elucidated, which will likely provide additional insights into the maintenance of remission in IBD patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03000101 . Registered on 21 December 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Scaioli E, Belluzzi A, Ricciardiello L, et al. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials. 2019. PMID: 31171016. doi:10.1186/s13063-019-3321-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。